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Abstract
Background—Chronic kidney disease (CKD) remains a prevalent public health problem that 
disproportionately affects African Americans, despite intense efforts targeting traditional risk 
factors. Periodontal disease, a chronic bacterial infection of the oral cavity, is both common and 
modifiable and has been implicated as a novel potential CKD risk factor. We sought to examine to 
what extent periodontal disease is associated with kidney function decline.
Methods—Retrospective cohort study of 699 African American participants with preserved 
kidney function defined by an estimated glomerular filtration rate (eGFR) >60ml/min/1.73m2 at 
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baseline who underwent complete dental examinations as part of the Dental-Atherosclerosis Risk 
in Communities study (1996–1998) and subsequently enrolled in the Jackson Heart Study (2000–
2004). Using multivariable Poisson regression we examined the association of periodontal disease 
(severe vs. non-severe) with incident CKD defined as incident eGFR<60ml/min/1.73m2 and rapid 
(5% annualized) eGFR decline at follow-up among those with preserved eGFR at baseline.
Results—Mean age at baseline was 65.4 years (SD 5.2) and 16.3% (n=114) had severe 
periodontal disease. There were 21 cases (3.0%) of incident CKD after a mean follow-up of 4.8 
(SD 0.6) years. Compared to participants with non-severe periodontal disease, those with severe 
periodontal disease had a 4-fold greater rate of incident CKD [adjusted incidence rate ratio 4.18, 
95% CI (1.68 – 10.39), p=0.002].
Conclusion—Severe periodontal disease is prevalent among a population at high-risk for CKD 
and is associated with clinically significant kidney function decline. Further research is needed to 
determine if periodontal disease treatment alters the trajectory of renal deterioration.
Keywords
renal insufficiency; chronic; periodontal diseases; risk factors; African Americans; disease 
progression
Compared with white individuals, African Americans are disproportionately affected by 
chronic kidney disease (CKD) and have nearly a four-fold greater risk of progression to end-
stage renal disease, a racial/ethnic disparity unparalleled in any other area of medicine.1, 2 
The reasons for this racial/ethnic disparity are not entirely explained by traditional CKD risk 
factors. Identifying novel, potentially modifiable CKD risk factors among African 
Americans is critical for identifying interventions aimed at reducing this excess burden of 
CKD.
Periodontal disease, a chronic infection of the oral cavity, also disproportionately affects 
racial and ethnic minorities and has been recently implicated as an independent risk factor 
for CKD.3–7 To date, two studies have found that severe periodontal disease (as defined by 
radiographic criteria among a cohort of Pima Indians with diabetes and by periodontal 
inflammation criteria in a cohort of elderly Japanese adults) is associated with an increased 
risk of kidney function decline over time.8, 9 However, the association of periodontal disease 
with kidney function decline over time among African Americans has not been explored.
In this study, we examine the association of periodontal disease with kidney function decline 
within a cohort of older African American adults over five years of follow-up. We 
hypothesized that individuals with severe periodontal disease would experience a greater 
likelihood of progression to clinically significant decreased kidney function than those 
without severe periodontal disease.
METHODS
Study Design and Population
We assembled a cohort of African American participants of the dental ancillary study to the 
Atherosclerosis Risk in Communities study (D-ARIC) who were subsequently enrolled in 
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the Jackson Heart Study (JHS). ARIC is a prospective community-based study of the causes 
and natural history of preclinical and clinical atherosclerotic disease. It included a 
probability sampling of eligible participants aged 45 to 64 years from 4 U.S. communities, 
including Jackson, Mississippi. D-ARIC was performed on a dentate (natural teeth present) 
subgroup of the ARIC cohort visit 4 (1996 to 1998) and consisted of an oral examination 
conducted by four study-calibrated dental hygienists.10 Participants requiring antibiotic 
prophylaxis for periodontal probing were excluded. Clinical measures collected included 
bleeding on probing, pocket probing depth, and gingival recession on 6 sites for all teeth. 
Clinical attachment level (CAL) was calculated from the distance in millimeters from the 
cementoenamel junction (CEJ) to the bottom of the gingival pocket. Similar to ARIC, JHS is 
also a prospective community-based cohort study designed to examine risk factors for 
cardiovascular disease among African Americans living in a tri-county area of Jackson, 
Mississippi. It enrolled participants and conducted an initial examination between 2000 and 
2004. JHS did not include an oral examination.
Because the current study was a secondary analysis of de-identified data, it was exempt from 
institutional review board (IRB) approval. D-ARIC and JHS had IRB approval and 
participant consent.
There were 755 D-ARIC (baseline) participants who went on to be enrolled in JHS 
approximately 5 years later (follow-up) (Figure 1). We excluded 19 participants without 
serum creatinine measures at baseline (n=12) or follow-up (n=7). Because our primary 
outcome included incident estimated glomerular filtration rate (eGFR)<60ml/min/1.73m2, 
we also excluded an additional 37 subjects who had eGFR<60ml/min/1.73m2 at baseline. 
The prevalence of severe periodontal disease by the Centers for Disease Control/American 
Academy of Periodontology (CDC/AAP) 2003 consensus definition (see below) was similar 
between these participants and the 699 participants with baseline eGFR≥60ml/min/1.73m2 
included in analysis (18.9% vs. 16.3%, p=0.7).
Predictor
Our primary predictor was periodontal disease. While there is no standard case definition for 
periodontal disease, the Centers for Disease Control/American Academy of Periodontology 
(CDC/AAP) 2003 consensus definition has been proposed as a standard definition of 
periodontal status for use in epidemiological studies.11 By CDC/AAP criteria, severe 
periodontal disease was defined as the presence of 2 or more interproximal sites with ≥ 6 
mm loss of attachment (AL) (not on the same tooth) and 1 or more interproximal site(s) with 
≥ 5 mm probing depth. Moderate periodontal disease was defined as 2 or more interproximal 
sites with ≥ 4 mm clinical AL (not on the same tooth) or 2 or more interproximal sites with 
probing depth ≥ 5 mm, also not on the same tooth. Mild periodontal disease was defined as 
≥ 2 interproximal sites with ≥ 3 mm AL and ≥ 2 interproximal sites with ≥ 4 mm probing 
depth (not on the same tooth) or 1 site with ≥ 5 mm.12
We examined the association of periodontal disease with kidney function decline 
categorizing CDC/AAP periodontal disease in several ways: (1) severe vs. non-severe (none, 
mild, or moderate); (2) any (mild, moderate, or severe) vs. none; and (3) a categorical 
definition (none, mild/moderate, or severe).
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Because periodontal disease is thought to lead to kidney dysfunction via an inflammatory 
pathway, we also defined periodontal status by the periodontal inflamed surface area (PISA) 
as a secondary predictor. PISA reflects the amount of inflamed periodontal tissue and was 
calculated for each participant using clinical attachment level, recession, and bleed on 
probing.13 We compared the highest quartile PISA vs. the other three PISA quartiles.
Main Outcome
Our main outcome of interest was incident CKD at follow-up (JHS visit), defined as 
estimated glomerular filtration rate (eGFR)<60ml/min/1.73m2 accompanied by rapid eGFR 
decline (>5% annualized loss). We used calibrated serum creatinine for calculation of eGFR 
as defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation14 Our definition of rapid decline is consistent with the Kidney Disease: Improving 
Global Outcomes (KDIGO) CKD Work Group definition of CKD progression and has been 
applied to other studies.15–17 Creatinine was measured by a multipoint enzymatic 
spectrophotometric assay and standardized to isotope dilution mass spectrometry (IDMS).18
Covariates
All covariates were defined using baseline (D-ARIC) data. Age, gender, smoking status, and 
annual income were obtained by self-report. Age was considered as a continuous variable. 
We defined smoking status as “never” or “former/current” and income as less than $25,000 
(reference), $25,000–$49,999, ≤ $50,000, or missing. We defined diabetes by fasting blood 
glucose ≥126mg/dl or self-reported use of hypoglycemic medications or insulin. 
Glycosylated hemoglobin data were not available. Hypertension was defined by a systolic 
blood pressure of ≥140 mm Hg, diastolic blood pressure of ≥90 mm Hg, or self-reported use 
of antihypertensive medications.
Statistical Analyses
We used multivariable Poisson regression to examine the association of periodontal disease 
defined by CDC/AAP and PISA with incident CKD over the study period. We adjusted for 
demographics (age and gender); comorbidities and health-related behaviors (hypertension, 
diabetes, and smoking); and socioeconomic status (income) as potential confounders. We 
added covariates to the model sequentially to examine incremental effects of each 
confounder category on the likelihood on incident CKD. Analyses were performed using a 
statistical software package. ‡‡
RESULTS
The average age in the study population at baseline was 65.4 (SD 5.2) years. The mean 
number of teeth examined was 17.9 (SD 7.5, range 2–32) and 86.3% had bleeding with 
probing around one or more teeth. The prevalence of examined sites with pocket probing 
depth ≥4mm and ≥5mm was 18.6% (SD 27.3) and 11.2% (SD 21.7), respectively. Mean 
pocket probing depth was 2.0mm (SD 0.7). The prevalence of examined sites with clinical 
attachment loss ≥3, ≥4mm and ≥6mm was 59.5% (SD 30.7), 25.3% (SD 31.7), and 8.5% 
(SD 20.1), respectively. Mean clinical attachment loss was 2.3mm (SD 1.0). By the 
CDC/AAP definition, 335 (47.9%), 17 (2.4%), 233 (33.3%), and 114 (16.3%) participants 
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had no, mild, moderate, and severe periodontal disease, respectively. Baseline characteristics 
by severe vs. non-severe periodontal disease are shown in Table 1. Age, income, and eGFR 
were similar across periodontal disease groups, as was the prevalence of hypertension. The 
prevalences of men, former or current smoking, and diabetes were significantly higher 
among those with severe periodontal disease.
Mean time to follow-up visit was 4.8 (SD 0.6) years and did not differ by periodontal 
disease status (p=0.6). At the follow-up visit, the median eGFR was 75.8ml/min/1.73m2 (SD 
19.2, interquartile range 63.0, 88.6). Thirty-one participants (4.4%) developed incident 
eGFR<60ml/min/1.73m2, 74 (10.6%) had rapid eGFR decline, and 21 (3.0%) had incident 
CKD (both incident eGFR<60ml/min/1.73m2 and rapid eGFR decline). Incident CKD was 
found among 10 (3.0%), 0 (0%), 2 (0.9%), and 9 (7.9%) of participants with no, mild, 
moderate, and severe periodontal disease respectively.
In the unadjusted model, severe periodontal disease was associated with a 3-fold greater rate 
of incident CKD [IRR 3.82, 95% CI (1.65 – 8.87), p=0.002] than non-severe periodontal 
disease (Table 2). This association appeared to get stronger with adjustment. In the fully 
adjusted model, severe periodontal disease was associated with a 4-fold greater rate of 
incident CKD [IRR 4.18 (1.68–10.39), p=0.002] than non-severe periodontal disease.
In the unadjusted model, any periodontal disease (mild, moderate, or severe) was not 
associated with greater rate of incident CKD than no periodontal disease (p=1.0). In the 
unadjusted model, the rate of incident CKD among those with mild/moderate periodontal 
disease was similar to that of those with no periodontal disease [IRR 0.27 (0.06–1.22), 
p=0.09] but was 2.6-fold greater among those with severe periodontal disease compared to 
those with no periodontal disease [IRR 2.63 (1.10–6.31), p=0.03 (Table 3). In the fully 
adjusted model, the strength of the association of severe periodontal disease with incident 
CKD compared to those with no periodontal disease increased [IRR 2.96 (1.14–7.67), 
p=0.02].
By the PISA definition, 9 (5.2%) participants in the highest quartile and 12 (2.3%) in the 
lower 3 quartiles had incident CKD. The highest PISA quartile group had a 2.5-fold greater 
rate of incident CKD than the lower 3 PISA quartiles after full adjustment [IRR 2.48 (1.04–
5.88), p=0.04] (Table 4).
DISCUSSION
In cohort of African Americans adults, we found that severe periodontal disease was 
consistently associated with incident CKD relative to less severe disease during a follow-up 
period of 5 years. In the unadjusted model, severe periodontal disease had a 3.8-fold 
increased rate of incident CKD, and after adjustment for age, sex, diabetes, hypertension, 
smoking status, and income, the association remained strong/increased. Interestingly, there 
appeared to be a threshold effect with respect to the severity of periodontal disease. When 
using quartiles of total periodontal inflamed surface area (PISA), the strength of association 
with CKD was attenuated, but remained significant. Furthermore, there was no association 
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of mild/moderate periodontal disease with CKD compared to those without periodontal 
disease.
Prior investigation of elderly Japanese participants found that those with severe periodontal 
disease, as defined by the highest PISA quartile, were twice as likely to have worsening 
eGFR category (≥ 60, 30–59, and ≤29 ml/min/1.73m2) after 2 years of follow-up than those 
without severe periodontal disease.8 However, worsening of eGFR category as an outcome 
may be problematic in that declines of significantly different sizes would be classified 
similarly, such as those from 50 to 29 and from 31 to 29 ml/min/1.73m2. Among a 
prospective cohort of Pima Indian adults with diabetes and eGFR>60ml/min/1.73m2 at 
baseline, severe periodontal disease, as defined by missing teeth and alveolar bone loss on 
panoramic radiograph, was associated with a 2-fold increased risk of incident 
macroalbuminuria and a 3.5-fold increased risk of incident end-stage renal disease over a 
follow-up of up to 22 years.9 Our study extends the current understanding of the association 
of periodontal disease with kidney function decline to an African-American population both 
with and without diabetes. An important strength of our study is that a full-mouth 
periodontal examination was performed, lending confidence in our ability to accurately 
define the prevalence of periodontal disease in the study population. Furthermore, our 
finding of an association of periodontal disease with both incident eGFR<60ml/min/1.73m2 
and rapid eGFR decline is novel and demonstrates the potential importance of periodontal 
disease on CKD progression.
Our findings are particularly important because periodontal disease is disproportionately 
more common among racial and ethnic minorities.3, 4 The strength of the association we 
found suggests that periodontal disease may be an important contributor to racial and ethnic 
disparities in CKD prevalence and progression. One prior study using Taiwanese insurance 
claim data found that patients with periodontal disease who underwent procedures of 
subgingival curettage and/or periodontal flap had a 40% lower likelihood of incident end-
stage renal disease (ESRD) as defined by ICD-9 codes than those who did not undergo those 
procedures.19 Given the low sensitivity of claims based ascertainment of ESRD, further 
investigation for the effect of treating periodontal disease on kidney function decline is 
warranted.20
Although periodontal disease is a local bacterial infection of the oral cavity, it is thought to 
exert an effect on kidney dysfunction via an inflammatory pathway because periodontal 
pathogens can access systemic circulation and potentially induce kidney injury through an 
innate immune response.21, 22 Therefore, it seems reasonable that the greatest association 
between periodontal disease and kidney function decline would be observed among those 
with the highest inflammatory burden, i.e. highest PISA quartile rather than among those 
with evidence of the most “end-stage” periodontal disease as found in our study. This 
finding suggests that the cumulative experience of periodontal disease may be an important 
contributor to the potential burden of kidney function decline.
Our study is not without limitations. First, because of the relatively small size of our study 
population, there were a limited number of outcomes. Therefore, we were restricted to a 
parsimonious model. Body mass index, for example, has been implicated as an independent 
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risk factor for CKD progression.23 Obesity was not included as a confounder in our 
analyses, but was highly prevalent in our study population (nearly half had body mass 
index≥30kg/m2) and was not different by periodontal disease status (p=1.0). Second, as with 
all observational studies, the association of periodontal disease with kidney function decline 
may be subject to residual confounding. However, given that we have accounted for the most 
important known confounders for periodontal disease and CKD, only one or more powerful 
unmeasured confounders could explain the strength of the association we found. Third, no 
interval periodontal disease treatment data or dental measures at follow-up were available. 
However, interval treatment or worsening of periodontal status would have likely biased 
findings toward the null if our hypothesis that severe periodontal disease leads to kidney 
function decline is true—treated patients would have slower decline in kidney function, 
while kidney function decline in those with interval worsening of periodontal disease would 
have been attributed to the milder periodontal disease at baseline. Finally, our study was 
limited to an older adult African American population, thus may not be generalizable to 
younger or non-African American cohorts. Further study is needed to determine if 
associations are similar across other races and age groups.
In conclusion, among a cohort at high-risk for CKD progression, severe periodontal disease 
was associated with incident clinically significant kidney function decline. Further research 
is needed to determine if the association is causal and, whether treatment of periodontal 
disease will alter the decline of eGFR.
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Table 1
Baseline participant characteristics, by periodontal disease status*
Characteristic Overall (n=699) Non-Severe (n=585, 83.7%) Severe (n=114, 16.3%) p-value†
Age in years, mean (SD) 65.4 (5.2) 65.4 (5.3) 65.2 (5.0) 0.7
Men, n (% column) 240 (34.3) 169 (28.9) 71 (62.3) <0.001
Smoking status former/current, n (%) 344 (49.5) 271 (46.6) 73 (64.0) 0.001
Hypertension, n (% column) 405 (58.1) 346 (59.3) 59 (51.8) 0.1
Diabetes, n (% column) 137 (19.7) 103 (17.7) 34 (29.8) 0.003
Income <$25,000, n (% column) 322 (46.1) 264 (45.1) 58 (50.9) 0.5
Estimated glomerular filtration rate (eGFR 
ml/min/1.73m2), median (interquartile range)
95.7 (83.2, 110.3) 95.7 (84.4, 110.3) 94.1 (81.4, 110.4) 0.2
Number of teeth examined, mean (SD) 17.9 (7.5) 17.6 (7.5) 19.1 (7.1) 0.05
Any bleeding on probing, n (% column) 603 (86.3) 489 (83.6) 114 (100%) <0.001
Pocket probing depth in millimeters (mm), mean 
(SD)
2.0 (0.7) 1.8 (0.4) 3.1 (0.9) <0.001
Prevalence of examined sites with pocket 
probing depth
 ≥4mm, % column (SD) 18.6 (27.3) 9.8 (16.4) 64.0 (26.9) <0.001
 ≥5mm, % column (SD) 11.2 (21.7) 3.8 (9.2) 48.9 (27.4) <0.001
Clinical attachment loss in millimeters (mm), 
mean (SD)
2.3 (1.0) 2.0 (0.5) 3.8 (1.4) <0.001
Prevalence of examined sites with clinical 
attachment loss
 ≥3mm, % column (SD) 59.5 (30.7) 53.1 (29.9) 92.2 (13.7) <0.001
 ≥4mm, % column (SD) 25.3 (31.7) 15.9 (22.7) 74.0 (25.9) <0.001
 ≥6mm, % column (SD) 8.5 (20.1) 2.1 (8.0) 41.8 (28.7) <0.001
*
Defined by Centers for Disease Control/American Academy of Periodontology criteria12
†
p-value is Kruskal-Wallis (eGFR, prevalence pocket probing depth and clinical attachment loss), t-test (age, number of teeth, mean pocket probing 
depth and clinical attachment loss), or Chi-square test (all other) of association between periodontal disease status and characteristic
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Table 2
Incidence-rate ratio of eGFR<60ml/min and rapid decline at 5-year follow-up by CDC/AAP* severe vs. non-
severe periodontal disease, N=699
Model Non-Severe (12/585)† Severe (9/114)†
IRR (95% CI) IRR (95% CI) p-value
unadjusted 1.0 (reference) 3.82 (1.65 – 8.87) 0.002
+ age, gender 1.0 (reference) 4.46 (1.91 – 10.38) 0.001
+ age, gender, diabetes, hypertension, smoking 1.0 (reference) 3.84 (1.50 – 9.79) 0.005
+ age, gender, diabetes, hypertension, smoking, income 1.0 (reference) 4.18 (1.68 – 10.39) 0.002
*
Centers for Disease Control/American Academy of Periodontology criteria12
†
n events/N subgroup
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Table 4
Incidence-rate ratio of eGFR<60ml/min and rapid decline at 5-year follow-up by PISA* highest quartile vs. 
lower 3 quartiles, N=699
Model Lower 3 quartiles (12/526)† Highest quartile (9/173)†
IRR (95% CI) IRR (95% CI) p-value
unadjusted 1.0 (reference) 2.29 (0.98 – 5.33) 0.06
+ age, gender 1.0 (reference) 2.49 (1.09 – 5.66) 0.03
+ age, gender, diabetes, hypertension, smoking 1.0 (reference) 2.42 (1.03 – 5.70) 0.04
+ age, gender, diabetes, hypertension, smoking, income 1.0 (reference) 2.48 (1.04 – 5.88) 0.04
*
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